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Abstract
Background: Around 30% of the population will experience herpes zoster (HZ), 10% of whom develop
postherpetic neuralgia (PHN). Together, these illnesses produce a significant economic burden to the healthcare
system.
Methods: Administrative healthcare data collected over the period of April 1st 1997 to March 31st 2014 were analyzed
to determine the healthcare system burden of HZ using direct medical costs. Episodes of HZ were identified using
international classification of disease (ICD) codes. Trends in age-adjusted (AA) HZ-rates were analyzed by piecewise-
regression. Total annual and per-episode costs were determined for drug treatment, medical care, and hospitalizations
within each year.
Results: The incidence of HZ increased by 49.5% from 1997/98 to 2013/14. Piecewise-regression of AA-rates revealed a
steady AA-rate of 4.7 episodes/1000 person-years (PY) from 1997/98 to a breakpoint in 2008/09, after which rates
began to increase reaching 5.7 episodes/1000 PY in 2013/14.
Drug costs rose significantly (p <0.03) from $89.77/episode (95% CI: $82.96, $96.59) to $127.34/episode (95% CI: $117.24,
$137.44). Medical costs increased (p <0.0001) from $57.98/episode (95% CI; $55.26, $60.70) to $78.84/episode (95% CI;
$74.08, $83.61). Hospitalization rates declined from 3.10% in 1997/98 to 1.36% in 2011/12, resulting in cost dropping
from $397/episode (95% CI; $284, $511) to $195/episode (95% CI; $129, $260).
Total annual costs of HZ and PHN were $1,997,183 in 2011/12, 4.7% lower than the 1997/98 costs of $2,095,633.
Conclusion: A significant increase in annual number of HZ cases was observed, driven largely by demographic
factors. A 21% increase in the AA-incidence reveals changes in HZ rates beyond those expected by population shifts.
The large increase in incidence of HZ, with rising per episode medical and prescription costs were offset by dramatic
drops in hospitalization rates, the net effect of which has been to hold the total costs relatively constant. However, the
decrease in hospitalization rates slowed over the last half of the study, settling at 1.3% in the last 4 study years. The
likely future of HZ burden is one of rising costs, primarily driven by the demographic shifts of an increasing and aging
population.
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Background
The varicella zoster virus (VZV) causes varicella zoster
(VZ) upon initial infection, affecting the skin and its sen-
sory neurons. As VZ resolves, the virus enters a latent
state in neuronal ganglia, remaining there for life [1–3].
Reactivation of VZV, typically within singular ganglia,
causes herpes zoster (HZ), a dermatological condition
similar in symptoms to VZ but causing moderate to
severe pain [4, 5]. A potential complication of HZ is
postherpetic neuralgia (PHN), a longer lasting pain syn-
drome caused by inflammation or virus-induced nerve
damage [4–6].
Before a VZ vaccine became available in 1999 (Varivax,
Merck Frosst Canada & Co), nearly all persons were
infected with VZV, typically as a child. By the age of 40,
VZV prevalence was 95–97% [7, 8]. Virtually this entire
pre-VZ vaccine population is at risk of developing HZ,
with an incidence estimated at between 1.2 and 6.3 cases
per 1000 person years (PY), with rates increasing with
age. The lifetime prevalence of HZ is between 20–30%,
rising to 50% by age 80 [2, 7, 9, 10].
The antiviral drugs acyclovir, valacyclovir, and famci-
clovir are the cornerstone of HZ treatment and reduce
the duration and severity of symptoms, including pain
[11]. Treatment should begin within 72 h of the onset of
symptoms and continue for 7 days [2, 6, 12]. Antiviral
drugs have been reported to account for 50–70% of the
drug cost for treated cases of HZ [13–16]. Other drugs
used to treat HZ pain include analgesics, opioids, gluco-
corticoids, and topical lidocaine.
Despite being relatively common, there is no a stand-
ard definition of PHN, particularly in reference to the
duration of pain which differentiates continuing HZ pain
from PHN. One of the more common criteria used is
the persistence of pain for 90 days or more post-HZ
diagnosis. Studies using this definition report that 5–
15% of HZ cases convert to PHN [13–15, 17–19]. PHN
is a challenging condition to treat. The Canadian Pain
Society consensus statement and the European Federation
of Neurological Societies (EFNS) treatment guidelines list
tricyclic antidepressants (TCAs), gabapentin, and pregaba-
lin as first line; and opioids or topical lidocaine as second
line treatment options for PHN [20, 21].
In randomized controlled trials, the HZ vaccine
(Zostavax®, Merck), introduced to Canada in September
2009, was shown to reduce the burden of HZ by 61%,
decrease the relative risk of HZ by 51%, and that of
PHN by almost 67% [16, 22–24].
A number of recent studies have looked at the burden
of HZ-PHN in a variety of health care systems, including
Belgium [25], France [26], Germany [14, 27], Greece [28],
Italy [13, 29], Spain [18], the United Kingdom [15], and
Israel [17]. However, little recent Canadian data have
been published. To establish the current burden of HZ
and PHN in the setting of a universal healthcare system,
and to look at long term trends in their treatment costs,
a retrospective, population based study was conducted
over the 15 year period from 1997/98 to 2011/12 in
Manitoba, Canada.
Methods
Using an observational, cohort-based methodology, the
incidence and burden of HZ and PHN were examined
from April 1st 1997 to March 31st 2014 using adminis-
trative healthcare data from the province of Manitoba,
Canada. Data was obtained from the Manitoba Centre
for Health Policy (MCHP), which maintains a data
repository containing records of virtually every contact
between Manitoba residents and the province’s universal
healthcare system [30, 31]. All records are de-identified
but contain a unique number that allows researchers to
link individual patient records across databases.
Databases used included the Drug Program Information
Network (DPIN), a community-pharmacy based prescrip-
tion processing system that enables submission of online
insurance claims by pharmacies, the Medical Services
database which contains records of fee-for-service medical
claims, Hospital Discharge Abstracts containing summary
data of each hospital stay; the Manitoba Immunization
Monitoring System (MIMS) database which contains re-
cords on vaccines administered in the population, and the
Manitoba Health Registry from which population counts
and basic demographics on individuals can be obtained.
Cases of HZ were identified using International Classi-
fication of Diseases (ICD) diagnostic codes. This method
has been shown to be highly selective (positive predictive
value 93%) and sensitive (97.5%) [32]. Individuals with
one or more ICD-9-CM (Clinical Modification) codes
starting with ‘053’, or ICD-10-CA (Canadian enhance-
ment) codes starting with ‘B02’ were classified as HZ
cases, with episodes starting on the date of the first code.
HZ was considered to have converted to PHN when
medical services claims or prescriptions for HZ were
received 90 days or more after diagnosis.
Multiple episodes of HZ were allowed provided two
conditions were met: 1) a minimum of 2 years had
elapsed since the start, and 2) a minimum of 180 days
had elapsed since the last HZ ICD code of the preceding
episode. To avoid misclassification of prevalent episodes,
episodes with start dates prior to April 1st 1997 were dis-
carded. Episodes in individuals under 20 years of age
were excluded from the analysis to avoid misclassifica-
tion of potentially miscoded VZ cases. Furthermore, to
avoid misclassification of physician visits regarding HZ
vaccine as episodes, the MIMS database was searched
for HZ vaccination records. As MIMS does not capture all
HZ vaccinations we also used DPIN to search for vaccine
prescriptions, and medical claims to find vaccination tariff
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codes, using these as surrogate markers of vaccination.
Any HZ episode starting within 30 days of vaccination
was excluded.
Pharmacotherapy was assessed using DPIN. Prescrip-
tions for acyclovir, valacyclovir, and famciclovir dis-
pensed in the first 30 days of an episode were classified
as HZ antiviral treatment. DPIN was searched by
Anatomical Therapeutic Chemical (ATC) class. Prescrip-
tions for nabilone (ATC class A04AD), local anesthetics
(D04A), systemic corticosteroids (H02A), NSAIDS (M01),
opioids (N02A), ASA, acetaminophen (N02B), anticonvul-
sants (N03A), and antidepressants (N06A) were catego-
rized as HZ pain prescriptions, provided that several
conditions were met: 1) treatment of pain with any drug
class began within 90 days following diagnosis; 2) use of a
drug class was incident to diagnosis; and 3) use after the
later of 90 days post-diagnosis and date of last ICD code
for HZ was continuous. Use within a drug class was
considered incident if less than 30 of the 90 days pre-
diagnosis had prescription coverage from that class.
Continuous use was defined as the ongoing dispensing of
prescriptions of the above-named ATC classes, with no
gaps between consecutive prescriptions greater than 200%
of the duration of the earlier prescription.
All costs were adjusted for inflation to 2013 Canadian
dollars using the Statistics Canada consumer price
index.
HZ episodes were further stratified into two subcat-
egories based on PHN status: HZ episodes with no
diagnosis of PHN (HZ-only), and HZ episodes that con-
verted to PHN (HZ-PHN). Costs were analyzed across
all HZ episodes, and then within each stratum separ-
ately. The Manitoba Pharmacare fiscal year (April 1st to
March 31st) was used for analysis over time. All costs
and events were considered to have been incurred in the
fiscal year of diagnosis.
Due to observation time required, two separate report-
ing periods are used. Epidemiology is reported from
1997/98-2013/14, as only a single observation is required
to diagnose HZ, and no follow-up time is required. For
burden analysis, two years of observable time is required
to capture costs accruing over episodes, especially for
HZ-PHN. Therefore, to capture all costs associated with
each episode and allow for equal follow-up time we only
report burden results of episodes initially diagnosed
before the end of the 2011/12 fiscal year.
Statistical analysis
The number of episodes and incidence rate of HZ, and
PHN conversion rates were calculated for each study
year. We calculated annual incidence rates (per thou-
sand person years) using population counts from the
Manitoba Health registry for that particular year. The
annual age-adjusted incidence rate was then determined
by calculating age group-specific rates, and using them
to directly standardize the overall incidence rate, with
the 1997 Manitoba age-distribution as our reference struc-
ture. A segmented regression analysis was conducted to
examine an apparent change in incidence of HZ. Ordinary
least squares (OLS) regression analysis was used for trend
analysis of costs and utilization. Due to non-linearity and
high variance a t-test was used to compare annual hospital
costs over the first (1997/98-2003/04) and last (2004/05-
2011/12) halves of the study period.
SAS® version 9.4 (SAS Institute, Cary, NC) and Micro-
soft Excel 2013® (Microsoft Corporation, Redmond WA)
were used for data analysis. Approvals were granted by
the University of Manitoba Health Research Ethics Board
and the Manitoba Health Information Privacy Committee.
Results
Epidemiological analysis: 1997/98 to 2013/14
A total of 73,886 episodes of HZ were diagnosed between
1997/98 and 2013/14, an overall crude incidence rate of
4.99 cases/1000 person-years (PY). As we have previously
reported [33], a sustained upward trend in the annual
numbers of HZ episodes was observed across the study
period (Table 1). There were 5,746 episodes of HZ identi-
fied in 2013/14, a 49.5% increase from 1997/98.
To adjust for the effects of an increase in the size and
age distribution, the age-adjusted (AA) incidence rate was
calculated and plotted (Fig. 1), revealing an abrupt change
in the observed trends in AA-rates starting around 2009/
10. Piecewise regression on the AA-incidence revealed a
breakpoint in July 2009 (F(3,13) = 59.6 p < 0.0001). Prior to
2009/10, the incidence of HZ remained relatively steady
(p = 0.96) at 4.70 cases/1000 PY (95% confidence interval
(CI): 4.65, 4.75). Starting in 2009/10 the AA-incidence
began increasing on average by 0.29 cases/1000 PY/year
(95% CI: 0.20, 0.37), reaching 5.70 cases/1000 PY in 2013/
14, a 21% increase from pre-2009/10 level.
Burden of disease analysis: 1997/98 to 2011/12
Drug utilization trends
Trends in drug utilization, medical claims cost, hospitali-
zations, and total cost were examined over the period
from 1997/98 to 2011/12.
Antiviral treatment rates increased from 41.7 to 62.9%
(F(1,13) = 220 p < 0.0001 R
2 = 0.94) over this period. The
cost per treated episode dropped from $139.61 to $96.20
due to the introduction of generic antiviral drugs. The
mean cost of pain treatment per episode increased by
over 111% for HZ, rising from $31.59 (95% CI: $25.35,
$37.84) to $66.81 (95% CI: $56.84, $76.79), and by 94%
for HZ-PHN, from $291 (95% CI: $225, $358) to $566
(95% CI: $478, $655) over the same interval. On average,
HZ-PHN episodes were responsible for 83% of pain-
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related drug costs, a proportion that remained un-
changed over time (p = 0.57).
The mean cost for all drug treatment rose significantly
(F(1,13) = 6 p < 0.03 R
2 = 0.32), from $89.77 (95% CI:
$82.96, $96.59) to $127.34 (95%CI: $117.24, $137.44).
This increase occurring within the first three study years
(Fig. 2). There was a significant upward linear trend in
the total annual drug cost (F(1,13) = 30.4 p < 0.0001 R
2 =
0.70), a result of the increase in the number of HZ cases
and the rise in mean per episode cost.
Fig. 1 Piecewise regression on age adjusted incidence of herpes zoster. The age adjusted incidence of herpes zoster was calculated using 1997
as the reference year for age standardization. A highly significant breakpoint was found in July 2009 (p < 0.0001). Varicella zoster vaccinations
were added to the routine childhood vaccination schedule in 2004. Abbreviations: VZV, varicella zoster vaccinations; BP, breakpoint; HZ, herpes
zoster; CI, confidence interval
Table 1 Overall health system burden of herpes zoster and postherpetic neuralgia in Manitoba, Canada
FY Year Cases Medical Services Hospitalization Drugs Annual Totals
HZ PHN Visits Cost Stays Cost Rxs Cost Overall PHN Only
1997/98 3844 331 9738 $222,864 119 $1,527,684 7842 $345,085 $2,095,633 $625,970
1998/99 3781 349 9311 $216,567 94 $947,462 8139 $346,495 $1,510,524 $521,352
1999/00 3941 367 9645 $240,928 97 $1,176,332 9927 $498,362 $1,915,623 $852,724
2000/01 3954 399 9981 $252,837 80 $978,360 9758 $475,111 $1,706,307 $622,177
2001/02 4060 429 10218 $268,900 95 $1,171,142 10548 $532,201 $1,972,243 $809,190
2002/03 4126 410 10549 $262,471 78 $1,116,598 10350 $523,136 $1,902,205 $507,749
2003/04 4070 375 10191 $275,353 83 $1,097,938 10169 $511,907 $1,885,197 $820,833
2004/05 4087 379 10291 $277,410 61 $621,227 9578 $504,787 $1,403,424 $406,629
2005/06 4131 432 10828 $286,785 49 $443,617 10507 $543,196 $1,273,598 $455,895
2006/07 4143 377 10849 $297,755 67 $924,959 10551 $530,623 $1,753,338 $473,495
2007/08 4207 377 11360 $314,783 72 $704,245 10679 $512,113 $1,531,142 $469,445
2008/09 4295 440 11615 $310,292 59 $809,855 12265 $555,622 $1,675,768 $400,491
2009/10 4584 427 12561 $355,407 58 $582,423 12456 $553,298 $1,491,129 $559,819
2010/11 4622 449 12998 $363,637 58 $627,314 12217 $578,973 $1,569,924 $633,618
2011/12 4984 497 13945 $392,947 68 $969,563 14439 $634,674 $1,997,183 $768,050
Abbreviations: FY fiscal year, HZ herpes zoster, PHN postherpetic neuralgia, Rxs prescription dispensations
Results were summarized by fiscal year with individuals episodes data considered to have occurred in year of diagnosis
All costs have been adjusted to 2013 Canadian dollars using Statistics Canada consumer price index
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Trends in medical care
An upward trend in utilization of medical services was
observed (F(1,13) = 59.5 p < 0.0001 R
2 = 0.82), The num-
ber of medical claims per episodes of zoster rose
slightly from 2.53 claims/episode (95% CI: 2.41, 2.65)
to 2.80 claims/episode (95% CI: 2.67, 2.93), while the
costs per medical claim rose 23% (F(1,13 = 59.9, p < 0.0001
R2 = 0.82). Together, these trends produced a linear
increase in the per episode cost (F(1,13 = 48.0 p < 0.00001
R2 = 0.76) from $57.98/episode (95% CI: $55.26, $60.70) in
1997/98, to $78.84/episode (95% CI: $74.08, $83.61) in
2011/12 (Fig. 2). The effect of these trends is amplified by
the increase in HZ cases resulting in a significant
increase in total annual medical costs (F(1,13 = 182.0
p < 0.0001 R2 = 0.93) (Table 1).
Hospitalization trends
The cost per HZ related hospitalization did not change
significantly over the study period with a mean of
$12,038/ hospitalization (95% CI: $11,068, $13,007). The
overall mean length of stay was 13.95 days (95% CI: 12.71,
15.19), this also did not change significantly (1997/98 vs.
2011/12 t = −1.62, p = 0.11). There was a sharp drop in the
rate of HZ-related hospitalization across the study period
(F(1,13) = 49.6 p < 0.0001 R
2 = 0.79), from 3.10% in 1997/98
(119 hospitalizations) to 1.36% in 2011/12 (68 hospitaliza-
tions). This resulted in the mean per episode cost of
hospitalization dropping significantly (F = 25.0 p = 0.0002
R2 = 0.62) from $397 (95% CI: $284, $511) to $195 (95%
CI: $129, $260), a decline of 51.0%.
Hospitalization costs accounted for 48.5% of total
costs in 2011, down from 72.9% in 1997/98. The mean
annual cost over the first half of the study (1997/98-
2003/04) was $1,145,074 (95% CI: $968,817, $1,321,331),
significantly higher than the mean cost of $710,400 (95%
CI: $560,336, $860465) seen over last half of the study
(2004/05-2011/12) (t(13) = 4.55, p = 0.0005).
Trends in total cost
The annual total health care costs of treating HZ are
shown in Table 1. Linear regression analysis revealed no
significant trend across the study period (p = 0.25) with
the total health system burden of HZ and PHN being
4.7% lower in 2011/12 than in 1997/98. While less than
10% of HZ episodes converted to PHN, they accounted
for almost 35% of total costs overall (Fig. 3).
Burden of herpes zoster in 2011/12
There were 4984 diagnosed episodes of HZ in 2011/12, an
incidence of 5.3 episodes/1000 PY. Of these, 497 went on
to develop PHN, a conversion rate of 10.0%. Hospitalization
accounted for 49% of total cost, medical services for 20%,
and prescription drug costs for 32%. Although PHN
occurred in only a tenth of all episodes, they were respon-
sible for 41.6% of hospital costs, 21.3% of medical cost, and
49.7% of drug costs. Overall, HZ-PHN episodes accounted
for 38.5% of total HZ-related costs.
The mean cost of an episode of HZ in 2011/12 was
$401 (95% CI: $318, $484). The mean cost for HZ that
converted to PHN (HZ-PHN), including the cost of
Fig. 2 Cost per episode of herpes zoster by treatment modality. The mean cost of treating herpes zoster was determined within each year and
regression analysis performed (solid lines). Significant trends were found for all modalities: prescription and medical costs p < 0.0001;
hospitalization p < 0.0002. All costs have been adjusted to 2013 Canadian dollars using Statistics Canada consumer price index
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treating PHN, was $1614 (95% CI: $1009, $2220). HZ
episodes not associated with PHN (HZ-only) had a mean
cost of $266 (95% CI: $204, $329), 16.5% of HZ-PHN
episodes.
The mean cost of treating an episode of HZ with pre-
scription drugs in 2011/12 was $127.34. Of this, 52.5%
was from the treatment of pain with a mean cost of
$66.81 (95% CI: $56.84, $76.78), the remainder arising
from antiviral treatment at a mean of $60.53 (95% CI:
$60.43, 59.92). For HZ-PHN episodes the mean drug
cost was $635 (95% CI: $547, $723) with pain treatment
accounting for 89% of this cost at $566/episode (95% CI:
$478, $655). HZ-only episodes had a mean drug cost of
$71.12 (95% CI: $69.18, $73.05), over 83% of which was
due to antiviral prescriptions treatment.
The average HZ episode in 2011/12 resulted in 2.80
(95% CI: 2.67, 2.93) medical claims for a mean cost of
$78.84 (95% CI: $74.08, $83.61). The average HZ-PHN
episodes resulted in 5.57 claims (95% CI: 4.86, 6.29) with
a mean cost of $168.30 (95% CI: $128.79, $207.81), while
the average HZ- only episodes resulted in 2.49 claims
(95% CI: 2.38, 2.60) with a mean cost of $68.93 (95% CI:
$66.08, $71.79).
HZ-related hospitalization was uncommon, and occurred
in 1.36% of episodes in 2011/12 with a mean cost per stay
of $14,258/hospitalization (95% CI: $9,461, $19,056). HZ-
PHN episodes were more frequently hospitalized at a rate
of 5.0%, whereas HZ-only episodes had a hospitalization
rate of 1.0%. There was no significant difference in the
cost per hospitalization between HZ-PHN and HZ-only
episodes so these results were combined. The cost of
hospitalization averaged across all HZ episodes was
$194.54 (95% CI: $115.90, $273.17).
Discussion
This study explored the burden of HZ in terms of health-
care system costs. A significant increase in the incidence
of HZ, independent of demographic shifts in the popula-
tion, was found to begin in 2009/10. The medical cost per
episode increased, as did total annual costs. There was an
increase in the per episode cost of drug treatment over
the first 3 years of study period, after which costs stabi-
lized and remained relatively constant. The combination
of these trends in per episode costs arising from medical
care and drug treatment were multiplied by the increase
in the annual incidence of HZ, causing total outpatient
costs to increase. However, this increase was offset by the
dramatic drop in rates of hospitalization and the resulting
decrease in hospital costs.
Although hospitalization is uncommon in HZ patients,
at a cost of $12,000 per stay it has a disproportionate
impact on the total burden. In 1997/98, hospital costs
accounted for almost three quarters of total HZ costs,
this proportion had dropped to 40–50% over the final
study years. This is a result of a dramatic change in rates
of hospitalization, which dropped from 3.10% in the first
study year to 1.36% in the last year. However, it appears
that this is the floor to hospitalization rates, as the
downward trend appears to have ended midway through
the study.
The same is not true regarding the trends seen in
number of cases, prescription drug costs, and medical
service utilization. The number of HZ cases increased by
50% from 1997/98 to 2013/14, largely driven by demo-
graphic changes. The cost per episode of medical care
has also seen sustained increases. Increasing costs of
pain treatment were offset by drops in antiviral costs
leaving the per-episode drug cost steady, however, the
increasing number of episodes has resulted in increasing
total drug costs. These trends do not appear to be slow-
ing down, and if hospitalization rates have indeed plat-
eaued, it may be the case that the burden of zoster will
increase in the future.
The 49.5% increase in the crude incidence of HZ,
which began to rise after 2009/10, is one of the most
Fig. 3 Overall Burden of Herpes Zoster: 1997/98 to 2011/12. The total
economic and epidemiologic burden of herpes zoster was determined
for the period from 1997/98 to 2011/12 and are shown in the above
figure. The inner circle shows the number of episodes broken down by
post-herpetic neuralgia (PHN) status, with the orange portion representing
episodes in which it occurred, while the outer ring breaks down the total
costs in 2013 Canadian dollars. While PHN accounted for less than 10% of
all episodes, it was responsible for 35% of total costs
Friesen et al. BMC Infectious Diseases  (2017) 17:69 Page 6 of 8
interesting results of this analysis. A significant portion
of this increase is related to demographic changes in the
province, namely, an increase in the population coupled
with an upward shift in the age distribution. However,
after controlling for these factors by calculating the inci-
dence rate, and adjustment of rates to a standard age
distribution, there remained a significant 21% increase in
HZ left to be explained.
One possible explanation is based on exposure to wild
VZV, circulating in the population, acting as an exogen-
ous boost to HZ cell-mediated immunity in latently
infected adults [34–36]. It has been proposed that an
unintended consequence of VZ vaccination programs
could be an increase in HZ rates. However, researchers
have found mixed evidence when searching for such an
effect at the population level [34, 37–42]. A study pub-
lished using data from Alberta, Canada also found an
increase in the rates of HZ. However, they reported that
this trend preceded the introduction of the VZ vaccine
[39]. Another Canadian study looking at this same issue
in Ontario found no increase in HZ rates [40]. However
that study ended just as the upward trend reported here
began. While this study was not designed to examine
such a relationship, it is interesting to note that the VZ
vaccinations were added to the routine schedule of
universally provided childhood vaccinations in 2004, just
5 years before the increase began. Uptake rates rose
quickly as the program was rolled out across various age
groups. By 2007/08 over 26% of all children under 18
had been vaccinated, and 76% of those who were sched-
uled to be vaccinated were [43].
While the HZ vaccine was introduced in 2009, it has not
been covered by the provincial insurance drug program
and has had limited uptake in Manitoba. As such, it is not
possible to assess the potential impact of the HZ vaccine on
the economic burden of HZ in Manitoba. However, some
jurisdictions are now providing the HZ vaccine free of
charge to those over age 65 [44]. In the future the impact
of wide spread use of the HZ vaccine in these jurisdictions
may allow a full assessment of the impact of vaccination on
HZ burden. An important limitation to our results on the
burden of HZ is that only direct medical expenses have
been considered. There are other sources of burden for
both patient and society outside of this narrow focus,
perhaps the most important being changes to individuals’
quality of life, especially for those individuals affected by
PHN. Societal costs such as lost productivity, disability
payments, and opportunity costs are also outside of the
scope of this study. However, this analysis has numerous
strengths, including the fact that costs are not estimated
based on models nor inferred from a sample but rather
directly measured across the entire provincial population.
This study examined 15 years of healthcare data, allowing
us to see changes over an extended period of time.
Conclusion
This study explored the burden of HZ in terms of health-
care system costs. A significant increase in the incidence
of HZ, independent of demographic shifts in the popula-
tion, was found to begin in 2009/10. The medical cost per
episode increased, as did total annual costs. Per-episode
drug costs remained level, with increased mean costs of
treating pain offset by decreases in antiviral cost per treat-
ment. The combination of increase per-episode medical
costs, and constant per-episode drug costs were multiplied
by increasing numbers of episodes, causing total out-
patient costs to increase. However, this was offset by a
dramatic drop in rates of hospitalization.
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